Business Description
Swedish Orphan Biovitrum AB
ISIN : SE0000872095
Total Employee Number:
1,969Compare
Compare
Traded in other countries / regions
SOBI.Sweden0MTD.UKSWOBY.USAB6E.Germany1SOBI.ItalySOBI N.Mexico IPO Date
2012-10-26Description
Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) in 2006 on long-acting hemophilia factor replacement programs. Biovitrum acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched hemophilia products Alprolix and Eloctate in Europe in 2016, and Altuvoct in 2024. Sobi has been building its immunology pipeline (rare-disease drug Gamifant, US rights to RSV antibodies Synagis and Beyfortus, gout drugs, complement drug Aspaveli) and a broader hematology pipeline (thrombocytopenia drug Doptelet, blood cancer drug Zynlonta, myelofibrosis drug Vonjo).
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.05 | |||||
Equity-to-Asset | 0.5 | |||||
Debt-to-Equity | 0.47 | |||||
Debt-to-EBITDA | 1.69 | |||||
Interest Coverage | 1.85 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 3.16 | |||||
Beneish M-Score | -2.62 | |||||
WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 10.5 | |||||
3-Year EBITDA Growth Rate | 17.5 | |||||
3-Year EPS without NRI Growth Rate | 18.1 | |||||
3-Year FCF Growth Rate | 16.2 | |||||
3-Year Book Growth Rate | 8.4 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 150.57 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 12.76 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 98.04 | |||||
9-Day RSI | 92.04 | |||||
14-Day RSI | 85.35 | |||||
3-1 Month Momentum % | 10.2 | |||||
6-1 Month Momentum % | 36.54 | |||||
12-1 Month Momentum % | 53.96 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.7 | |||||
Quick Ratio | 0.47 | |||||
Cash Ratio | 0.04 | |||||
Days Inventory | 261.8 | |||||
Days Sales Outstanding | 72.77 | |||||
Days Payable | 60.79 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -3.7 | |||||
Shareholder Yield % | 1.15 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 77.87 | |||||
Operating Margin % | 4.75 | |||||
Net Margin % | 3.18 | |||||
EBITDA Margin % | 39.08 | |||||
FCF Margin % | 13.81 | |||||
OCF Margin % | 25.54 | |||||
ROE % | 2.39 | |||||
ROA % | 1.3 | |||||
ROIC % | 1.93 | |||||
3-Year ROIIC % | -17.13 | |||||
ROC (Joel Greenblatt) % | 48.1 | |||||
ROCE % | 2.47 | |||||
Years of Profitability over Past 10-Year | 10 | |||||
Moat Score | 6 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 188.58 | |||||
Forward PE Ratio | 23.52 | |||||
PE Ratio without NRI | 26.42 | |||||
Shiller PE Ratio | 54.15 | |||||
Price-to-Owner-Earnings | 27.43 | |||||
PEG Ratio | 2.75 | |||||
PS Ratio | 5.76 | |||||
PB Ratio | 4.1 | |||||
Price-to-Free-Cash-Flow | 41.74 | |||||
Price-to-Operating-Cash-Flow | 22.56 | |||||
EV-to-EBIT | 133.86 | |||||
EV-to-Forward-EBIT | 21.89 | |||||
EV-to-EBITDA | 16.26 | |||||
EV-to-Forward-EBITDA | 15.52 | |||||
EV-to-Revenue | 6.36 | |||||
EV-to-Forward-Revenue | 5.73 | |||||
EV-to-FCF | 45.95 | |||||
Price-to-GF-Value | 1.34 | |||||
Price-to-Projected-FCF | 2.12 | |||||
Price-to-DCF (Earnings Based) | 0.67 | |||||
Price-to-DCF (FCF Based) | 1.38 | |||||
Price-to-Median-PS-Value | 1.4 | |||||
Price-to-Peter-Lynch-Fair-Value | 2.07 | |||||
Earnings Yield (Greenblatt) % | 0.75 | |||||
FCF Yield % | 2.4 | |||||
Forward Rate of Return (Yacktman) % | 15 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return %
Total Annual Return %
Swedish Orphan Biovitrum AB Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil kr) | 28,955 | ||
| EPS (TTM) (kr) | 2.54 | ||
| Beta | 0.4675 | ||
| 3-Year Sharpe Ratio | 1.09 | ||
| 3-Year Sortino Ratio | 2.15 | ||
| Volatility % | 22.31 | ||
| 14-Day RSI | 85.35 | ||
| 14-Day ATR (kr) | 1.980666 | ||
| 20-Day SMA (kr) | 447.72 | ||
| 12-1 Month Momentum % | 53.96 | ||
| 52-Week Range (kr) | 267.2 - 463.8 | ||
| Shares Outstanding (Mil) | 345.85 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Swedish Orphan Biovitrum AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Swedish Orphan Biovitrum AB Stock Events
| Event | Date | Price (kr) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-10-27 | In 111 days | ||
| Third quarter earnings results for 2026 | 2026-10-27 | In 111 days | ||
| Second quarter earnings conference call for 2026 | 2026-07-16 | In 8 days | ||
| Second quarter earnings results for 2026 | 2026-07-16 | In 8 days | ||
| General meeting for 2026 | 2026-05-06 | 423.60 (+0.00%) | ||
| First quarter earnings conference call for 2026 | 2026-04-28 12:30 | 418.60 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-04-28 08:00 | 418.60 (+0.00%) | ||
| Annual report for 2025 | 2026-03-31 | 385.80 (+0.00%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-02-05 13:00 | 357.60 (+0.20%) | ||
| Fourth quarter earnings results for 2025 | 2026-02-05 08:00 | 357.60 (+0.20%) |
Show
Entries
Swedish Orphan Biovitrum AB Frequently Asked Questions
What is Swedish Orphan Biovitrum AB(CHIX:SOBIs)'s stock price today?
The current price of CHIX:SOBIs is kr463.20. The 52 week high of CHIX:SOBIs is kr463.80 and 52 week low is kr267.20.
When is next earnings date of Swedish Orphan Biovitrum AB(CHIX:SOBIs)?
The next earnings date of Swedish Orphan Biovitrum AB(CHIX:SOBIs) is 2026-07-16.
Does Swedish Orphan Biovitrum AB(CHIX:SOBIs) pay dividends? If so, how much?
Swedish Orphan Biovitrum AB(CHIX:SOBIs) does not pay dividend.
Press Release
Articles on Swedish Orphan Biovitrum AB
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers